RiMO Therapeutics, LLC is a privately held nano-pharmaceutical company founded by Professor Wenbin Lin of the University of Chicago. Headquartered in Elk Grove Village, Illinois, the Company is dedicated to developing and commercializing the nanoscale coordination polymer (NCP) technology. RiMO’s proprietary NCP platform eliminates tumors from a dozen different mouse models at X-ray doses that are only one to ten percent of the current radiotherapy X-ray doses. The RiMO technology also significantly enhances the efficacy of immunosuppression inhibitor based cancer immunotherapy.